Clinical Trials Browser

Phase 1 × INDUSTRY × trastuzumab deruxtecan × Clear all

Breast Neoplasms

NCT04686305 2026-04-13

DL03

Phase 1 Recruiting

304 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT07015697 2026-03-20

A Study of Subcutaneous Trastuzumab Deruxtecan in Participants With Metastatic Solid Tumors

Phase 1 Recruiting

76 enrolled

Recurrence

NCT06244485 2026-02-04

A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors

Phase 1 Recruiting

210 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT04556773 2025-12-17

DB-08

Phase 1 Active not recruiting

138 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04042701 2025-11-18

DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer

Phase 1 Active not recruiting

115 enrolled

BreastThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT03523572 2025-01-27

Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial Cancer

Phase 1 Completed

86 enrolled 22 charts

BreastGenitourinary

Breast Neoplasms, Carcinoma, Transitional Cell, Neoplasm Metastasis

NCT02564900 2024-01-22

Study of DS-8201a in Subjects With Advanced Solid Malignant Tumors

Phase 1 Completed

292 enrolled 35 charts 1 FDA

Tumor-Agnostic

Neoplasms

NCT03383692 2023-12-11

Study of DS-8201a for Participants With Advanced Solid Malignant Tumors

Phase 1 Completed

40 enrolled 20 charts

Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT03368196 2022-11-03

DS-8201a in Patients With Cancer That Tests Positive for Human Epidermal Growth Factor Receptor 2 (HER2) Protein

Phase 1 Completed

12 enrolled 15 charts

BreastGastrointestinal

Adenocarcinoma, Breast Neoplasms, Neoplasms, Stomach Neoplasms

NCT03366428 2022-04-12

Phase 1 Study to Evaluate the Effect of DS-8201a on the QT/QTc Interval and Pharmacokinetics in HER2-Expressing Breast Cancer

Phase 1 Completed

51 enrolled 14 charts

Breast

Breast Neoplasms, Neoplasms

Clinical Trials

A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors

DL03

A Study of Subcutaneous Trastuzumab Deruxtecan in Participants With Metastatic Solid Tumors

A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors

DB-08

DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer

Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial Cancer

Study of DS-8201a in Subjects With Advanced Solid Malignant Tumors

Study of DS-8201a for Participants With Advanced Solid Malignant Tumors

DS-8201a in Patients With Cancer That Tests Positive for Human Epidermal Growth Factor Receptor 2 (HER2) Protein

Phase 1 Study to Evaluate the Effect of DS-8201a on the QT/QTc Interval and Pharmacokinetics in HER2-Expressing Breast Cancer